Adaptive outlines MRD separation plan while raising 2026 MRD revenue guidance to $268M-$278M (NASDAQ:ADPT)
· seekingalpha.com
Adaptive Biotechnologies (ADPT) Q2 2026 earnings call: MRD surge lifts guidance to $268–$278M; separation plan, margins & cash.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...